PF-00610355
- Generic Name
- PF-00610355
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C34H39N3O6S
- CAS Number
- 862541-45-5
- Unique Ingredient Identifier
- ZH5SMU97AJ
- Background
PF-00610355 has been used in trials studying the treatment of Lung Disease, Moxifloxacin, Pulmonary Disease, Asthma, Bronchial, and Bronchial Diseases, among others.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Investigate the Effects of PF00610335 on the QT/QTC Interval in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-04-20
- Last Posted Date
- 2011-01-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT01107054
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00830427
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2019-02-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 405
- Registration Number
- NCT00808288
- Locations
- 🇹🇷
Pfizer Investigational Site, Izmir, Turkey
Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2010-11-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00783406
- Locations
- 🇩🇪
Pfizer Investigational Site, Wiesbaden, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath